These results can be explained by the fact that SFRP5 is an anti-inflammatory molecule that seems to have a protective role in the first steps of hepatic steatosis, but then the inflammation seems to deregulated SFRP5 signaling, blocking its inhibition of the noncanonical WNT pathway, which promotes NAFLD progression. Here, SFRP5 is linked to Hepatic steatosis.